A 52 week double blind randomized controlled trial comparing the effect of rosiglitazone versus placebo on the prevention of progression of atherosclerosis in high risk patients without diabetes.

Trial Profile

A 52 week double blind randomized controlled trial comparing the effect of rosiglitazone versus placebo on the prevention of progression of atherosclerosis in high risk patients without diabetes.

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 May 2012

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Atherosclerosis; Metabolic syndrome
  • Focus Therapeutic Use
  • Acronyms RUBENS
  • Most Recent Events

    • 24 Nov 2009 New source identified and integrated (Netherlands Trial Register; NTR307)
    • 17 Dec 2008 Status changed from not stated to completed as reported by ISRCTN: Current Controlled Trials.
    • 20 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top